We have determined the pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of rocuronium in infants and children. We studied infants (n = 5, 0.1-0.8 yr) and children (n = 5, 2.3-8 yr), ASA II, in the ICU while undergoing artificial ventilation under i.v. anaesthesia with an arterial cannula in situ and the EMG of the adductor pollicis muscle was monitored. Rocuronium 0.06 (infants) and 0.09 (children) mg kg(-1) min(-1) was given i.v. over +/- 5 min until 85% neuromuscular block was obtained. Arterial blood samples were obtained over 240 min. Plasma concentrations were measured by HPLC. Pharmacokinetic-dynamic variables were calculated using the Sheiner model and the Hill equation. Statistical analysis was performed using the M...
BACKGROUND AND OBJECTIVE: This study clarifies the relationship between the neuromuscular blocking e...
Background Target-controlled infusion (TCI) has been recently developed and successfully implemented...
Rapacuronium (Org 9487) is a rapid-onset and short- to intermediate-acting muscle relaxant. Its 3-de...
We have determined the pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of rocuroni...
The existing human pharmacokinetic studies have been reviewed and compared with data derived from an...
Rocuronium is a new non-depolarising agent with an intermediate time-course of neuromuscular blockin...
We have studied dose requirements, recovery times and pharmacokinetics of rocuronium in 32 intensive...
We have studied the pharmacokinetics of a single bolus of rocuronium (Org 9426), followed by an infu...
The pharmacokinetic-pharmacodynamic relationship of rocuronium at the laryngeal adductor muscles and...
Patients with myasthenia gravis are more sensitive than healthy patients to nondepolarizing neuromus...
We studied the onset and duration of action and pharmacokinetics of rocuronium bromide during anaest...
BACKGROUND AND OBJECTIVE: This study clarifies the relationship between the neuromuscular blocking e...
Background Target-controlled infusion (TCI) has been recently developed and successfully implemented...
Rapacuronium (Org 9487) is a rapid-onset and short- to intermediate-acting muscle relaxant. Its 3-de...
We have determined the pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of rocuroni...
The existing human pharmacokinetic studies have been reviewed and compared with data derived from an...
Rocuronium is a new non-depolarising agent with an intermediate time-course of neuromuscular blockin...
We have studied dose requirements, recovery times and pharmacokinetics of rocuronium in 32 intensive...
We have studied the pharmacokinetics of a single bolus of rocuronium (Org 9426), followed by an infu...
The pharmacokinetic-pharmacodynamic relationship of rocuronium at the laryngeal adductor muscles and...
Patients with myasthenia gravis are more sensitive than healthy patients to nondepolarizing neuromus...
We studied the onset and duration of action and pharmacokinetics of rocuronium bromide during anaest...
BACKGROUND AND OBJECTIVE: This study clarifies the relationship between the neuromuscular blocking e...
Background Target-controlled infusion (TCI) has been recently developed and successfully implemented...
Rapacuronium (Org 9487) is a rapid-onset and short- to intermediate-acting muscle relaxant. Its 3-de...